Retractable Technologies is a founder-controlled safety-syringe maker whose second-quarter profit came from selling securities, not from selling needles. VanishPoint and EasyPoint still sit inside a Little Elm plant that loses money every quarter. The operating loss held near $5 million even as headline earnings flipped positive. That split is the whole case. The market is capitalizing a securities book and a pandemic-era factory, while the commercial franchise has not covered its own cost base since the vaccine boom faded.
Unit volumes fell because EasyPoint orders slipped and last year's flu-season buying sat in the second quarter rather than the third. Sales dropped about 31% as a result. Gross profit barely turned positive after a year-ago gross loss, yet operating expense did not shrink with volume. A realized gain near $6 million on equity sales, plus Technology Investment Agreement amortization, produced the printed profit. Cash from operations stayed negative in the first half. The securities book is doing the work the syringe line is not.
An April workforce cut of 16% is the first real attempt to shrink the cost base to the post-pandemic run rate. Domestic output is rising, but more than half of units still come from Chinese plants facing a tariff above one hundred percent. Book value remains several times the share price. The question for the next several quarters is whether Little Elm can earn a gross margin that funds overhead without another securities sale.